Navigation Links
Major Discovery Raises Prospect of Better Patient Care By Improving,Platelet Life Span

MELBOURNE, Australia, March 23, 2007 /PRNewswire/ -- Scientists at WEHI have made a discovery with potentially profound implications for the care of patients, especially those undergoing cancer chemotherapy.

The research team led by Drs Benjamin Kile and David Huang has discovered that platelet life span is controlled by two key molecules. The discovery raises the prospect of developing a new drug to prolong the life span of platelets stored in blood banks, effectively increasing the availability of this life-saving blood product.

An undesirable side effect of cancer chemotherapy is extensive bruising and potentially life-threatening bleeding. This is caused by the unintended depletion of platelets, tiny circulating blood cells that are essential for blood clotting and wound healing. Consequently, the well being of some patients depends upon platelet transfusions, particularly during the vulnerable periods that follow anti-cancer treatment. The significant demand for high quality platelets, coupled with their short shelf life of only five days, presents major logistical challenges in clinical practice.

The scientific team has found that two specialised molecules act in opposition to each other to control platelet life span by regulating the process known as "apoptosis." This term refers to the normal and healthy self destruction of old, damaged and surplus cells. One protein (known as Bcl-xL) acts to preserve the life of the platelet, while the other protein (Bak) prepares the cell to self-destruct after its usual life span within the body - - about a week.

WEHI's Dr David Huang said, "Apoptosis is an essential process, common in other cells, but the central role it plays in controlling the life span of the highly specialised platelet has not been previously appreciated. With this new knowledge, we are in a much stronger position to devise better therapies for the management of plate let-related diseases."

Dr Kile added, "For fifty years doctors have speculated about what controls platelet life span. We now know the identity of the precise molecular switch responsible. The team is now actively pursuing a drug development program aimed at manipulating this switch in order to prolong the life span of blood bank platelets, increasing their availability to patients receiving cancer treatment and others in danger of serious bleeding".

At the opposite end of the scale, shortening platelet life span may be useful in the treatment of other diseases. For instance, too many platelets can trigger dangerous blood clots leading to strokes or heart attacks. Reducing platelet life span may therefore prove valuable in the prevention and management of these life-threatening conditions.

Refer to the illustration which can be viewed at http://www.asianetnews.net

The scientific research was generously funded by the Australian National Health and Medical Research Council (NHMRC); the State Government of Victoria (DIIRD); the Australian Research Council (ARC); the Australian Cancer Research Foundation (ACRF); the Cancer Council of Victoria (CCV); the National Cancer Institute (US); the US-based Leukemia and Lymphoma Society (www.lls.org); and MuriGen Pty Ltd (www.murigen.com.au), a company based at the WEHI Biotechnology Centre in Bundoora, Victoria.

The scientific teams, headed by Dr Kile and Dr Huang and based at WEHI, include: Dr Kylie Mason, Dr Marina Carpinelli, Dr Jamie Fletcher, Dr Janelle Collinge, Ms Adrienne Hilton, Ms Sarah Ellis (Peter MacCallum Cancer Centre), Ms Priscilla Kelly, Dr Paul Ekert (Children's Cancer Centre, Royal Children's Hospital), Professor Donald Metcalf and Dr Andrew Roberts.

The findings of the scientific team are published in the 23 March 2007 issue of the prestigious international journal, Cell.

    Dr Benjamin Kile and Dr David Huang are available for interview.


    Contact:

    Mr Brad Allan,

    WEHI Communications Manager

    Telephone: +61 3 9345 2345; mobile 0403036116.

    Email 

allan@wehi.edu.au

Eliza Hall Institute Of Medical Research (WEHI)

CONTACT: Mr Brad Allan, WEHI Communications Manager, +61 3 9345 2345, ormobile, 0403036116, or allan@wehi.edu.au

Web site: http://www.asianetnews.net/

Terms and conditions of use apply
Copyright © 2007 PR Newswire Association LLC. All rights reserved.
A United Business Media Company


'"/>




Related medicine technology :

1. International ENDORSE Study Shows That the Majority of Hospitalized Patients Surveyed are at Risk for VTE and Many do not Receive Recommended VTE prophylaxis
2. Major New Review Supports the Broader Potential of CeNeS COMT Inhibitor Discovery Programme
3. New Study Results Provide Additional Data about Short- and Long-Term Use of Desvenlafaxine Succinate in the Treatment of Adults with Major Depressive Disorder
4. Pooled Studies Showed Desvenlafaxine Succinate Significantly Improved Painful Symptoms and Anxious Symptoms Associated with Major Depressive Disorder in Adults, Compared With Placebo
5. Six-Week Investigational Study In Adults With Major Depressive Disorder Evaluates The Effectiveness of Adjunctive Aripiprazole Therapy With Antidepressants
6. Major Manufacturer of Unapproved and Adulterated Drugs
7. Exforge Helps Vast Majority of Patients Effectively Control Their Blood Pressure After Failing on Other Medicines, According to New Clinical Data
8. CuraGen and TopoTarget Announce New Clinical Results With Belinostat to be Reported at Upcoming Major Medical Meetings
9. Introgen Presents ADVEXIN Biomarker Data at Major Cancer Conference
10. Schering-Plough Addresses Major Milestones and Challenges in Treatment of Patients With Chronic Hepatitis C
11. New Clinical Data for Cytogens Quadramet and Prostacint to be Reported at Upcoming Major Medical Meetings
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/2/2016)... , December 2, 2016 ... "In Vitro Diagnostics/IVD Market by Product (Instruments, Reagents, ... Application (Diabetes, Oncology, Cardiology, Nephrology, Infectious Diseases) - ... market is valued at USD 60.22 Billion in ... a CAGR of 5.5% during the forecast period ...
(Date:12/2/2016)... 2016  The Addiction Treatment Advisory Group (ATAG), ... Care Pharmacy (AMCP), has released detailed findings on ... opioid addiction crisis, including through improved access to ... ATAG,s newly released paper, "The Role of Managed ... many issues around gaps and barriers to addiction ...
(Date:12/2/2016)... 2, 2016 Boston Scientific Corporation (NYSE: ... acquire certain manufacturing assets and capabilities of the Neovasc, ... biological tissue business, as well as a 15% equity ... in cash. The Neovasc advanced biological tissue business makes ... Scientific Lotus™ Valve System. * Upon completion of ...
Breaking Medicine Technology:
(Date:12/2/2016)... ... 02, 2016 , ... ‘Tis the season for giving! Today, 20 creative teams ... Family Partnership and the Drug Enforcement Administration as part of the National Red Ribbon ... winning schools who decorated their campuses with this year’s Red Ribbon Week theme: “YOLO. ...
(Date:11/30/2016)... ... November 30, 2016 , ... Northridge ... in-house dental plan for all patients. Understanding that budget can play a part ... a number of perks, including discounts on many valuable dental treatments. Options for ...
(Date:11/30/2016)... Wisconsin (PRWEB) , ... November 30, 2016 , ... ... in the 2016 Deloitte Wisconsin 75, an annual ranking and recognition of the ... year on the list, having ranked from 2008-2016. In addition, Standard Process was ...
(Date:11/30/2016)... (PRWEB) , ... November 30, 2016 , ... ... and mental health treatment has announced the opening of a new residential mental ... for girls with mental health issues such as severe anxiety, depression, bi-polar disorder, ...
(Date:11/30/2016)... ... November 30, 2016 , ... The ... stylish design wanted by today’s consumers at an affordable price, is now available ... the new watch is “a game changer” when it comes to the smartwatch. ...
Breaking Medicine News(10 mins):